Could there really be a weight loss drug that outperforms both Ozempic and Mounjaro? 🤯
In this video, we’re diving deep into Retatrutide — the groundbreaking next-generation peptide that’s producing some of the most impressive weight loss results ever seen in clinical trials. While it’s not FDA-approved yet, the data has doctors, researchers, and patients paying very close attention. 👀
Retatrutide isn’t just another GLP-1 medication. Unlike Ozempic (semaglutide) and Mounjaro (tirzepatide), it works on THREE metabolic pathways simultaneously, earning it the nickname: “The Triple Agonist.” 💉⚡
We’ll break down: ✅ What Retatrutide is ✅ How it compares to Ozempic and Mounjaro ✅ Why patients are seeing dramatic weight loss results 📉 ✅ The science behind GLP-1, GIP, and glucagon receptors 🧬 ✅ Clinical trial data and real-world outcomes 📊 ✅ Potential side effects and risks ⚠️ ✅ Why it hasn’t received FDA approval yet 🏛️ ✅ What you should know before considering it
If you’ve been following the explosion of weight loss medications and want to understand what may be the future of obesity and diabetes treatment, this video is for you.
💡 Whether you’re a healthcare professional, biohacker, fitness enthusiast, or someone exploring medical weight loss options, this breakdown will help you separate the hype from the science.
👇 Let us know in the comments: Would you consider trying Retatrutide if it becomes FDA-approved?
👍 Like this video if you found it helpful 🔔 Subscribe for evidence-based health, longevity, and metabolic health content 📢 Share this video with someone interested in weight loss breakthroughs
Dr. Ahmet Ergin discusses Retatrutide, a potent \"triple agonist\" peptide for obesity and type 2 diabetes. It targets GLP-1, GIP, and glucagon receptors, offering superior weight loss (24-26%) and metabolic improvements compared to Semaglutide and Tirzepatide. While not yet FDA-approved, it is available via licensed compounding pharmacies under strict physician supervision.
Hello everybody, this is Dr. Ahmet Ergin. I'm an endocrinologist, I'm a diabetes and weight loss specialist.
Today we are talking about something crazy good.
There is a peptide being compounded at select pharmacies right now that is producing results in diabetic and obese patients
that are genuinely hard to believe until you look at the data.
It is not FDA approved yet and it's not a household name yet either.
But in clinical practice, patients on it are losing significant weight,
dropping their A1c, improving their blood pressure,
and doing things that drugs on the market right now for decades could not accomplish,
including Yolozempic and Monjaro.
Now this new one is called Letaturotide.
And today we are breaking down exactly what it is, how it compares to everything else out there,
and why it is not FDA approved yet.
And what you need to know before you even think about pursuing it.
First, what makes Letaturotide different, right?
To understand Letaturotide, you need to understand how the current generation of weight loss and diabetes drugs work.
Now you have heard of Semibilotide, that is Yolozempic, and we go with it.
It targets one receptor, GLT1.
It's a glucagon-like peptide now.
With slow digestion, it reduces appetite, improves insulin secretion, lowers blood sugar.
It works well. Millions of people are on it.
Then came Perzepatide, that is Monjaro, Zepam.
It targets two receptors, GLT1 and GIP.
This is glucose-dependent insulin product peptide.
Adding the second receptor made it significantly more powerful for weight loss.
Better glucose control, better outcomes than Semibilotide in test-to-test trials when it comes to weight loss and weight loss.
Semibilotide, or Zempic, still wins when it comes to cardiovascular risk reduction drugs.
Retratertide hits three receptors, GLT1, GIP, and glucagon.
Glucagon is a mutant, right?
It's a triple agonist.
That is why it is being called the triple food.
The glucagon receptor is the key upgrade here.
Glucagon normally raises blood.
We give glucagon to patients who are on insulin in case they get a severe low blood sugar.
When you activate the glucagon receptor in the right metabolic context,
which is alongside GLT1 and GIP, something totally different happens.
It dramatically increases energy expenditure, so your basic metabolic rate goes up.
It accelerates fat burning, specifically visceral fat, the dangerous fat around your organs.
It ramps up the body's metabolic rate in a way that dual agonists cannot match.
This is not incremental environment.
The phase 2 trial results published in the New England Journal of Medicine show that participants losing an average of 24% of their body weight over 48 weeks at the highest dose.
Some patients hit 26%.
To put that in context, for example, semaglutide averages tops at 15% and tezapatite tops at 20%, maybe 22%.
Ritazirotide is definitely outperforming everything currently on the map.
What does this mean for diabetics, specifically for type 2 diabetics?
Ritazirotide is hitting multiple targets simultaneously.
The GLP activation increases insulin secretion as well in a glucose-dependent manner,
meaning that if your glucose is not high, the GLP1 receptor will not be activated.
And it triggers insulin only when your blood sugar is elevated.
Makes sense, right?
This dramatically reduces the risk of hyperglycemia, low blood sugar, compared to traditional diabetes derived by glucoside, glycolide, etc.
GIP activation improves insulin sensitivity and also plays a role in reducing insulin resistance at the cellular level.
GLP1 receptor activation, paradoxically, supports better glucose regulation in this triple combination form,
because the body's metabolic state is being shifted fundamentally.
This means less glucose production in the liver, more energy burned from fat stores.
Now, patients in clinical settings are seeing a bouncy drop today, clinically very significant.
Blood pressure is improving, liver fat is reducing, fatty liver disease is going away,
because it's one of the most under-diagnosed conditions in type 2 diabetics.
I do a lot of extra testing, blood testing and liver ultrasound, sometimes a lastography for my patients,
to determine and reverse the fatty liver in them.
That helps, right?
Helping the fatty liver helps a lot of us.
Also cardiovascular risk matters.
Now, this is not just a weight loss drug, okay?
For a diabetic, this is addressing physically underlying metabolic dysfunction from multiple angles at once.
And this is a peptide, okay?
So, we have peptides in our body.
That's not a very important substance.
So, here's the compounding outcome, what you must understand.
We have to be completely clear with you.
Leptoturtonic is not FDA approved.
So, don't start going online, on the gray market, from websites that have no FDA oversight,
and buy yourself a Leptoturtonic.
People do that, and I don't know how.
Because when you inject something to your body, there is no protective mechanism.
Your stomach cannot kill it.
Your intestine cannot digest it.
It cannot go through your liver to be processed.
So, anything you go through under the skin, it goes right to your blood.
What if these things are contaminated?
What if these things are having ingredients that are toxic to the body?
Because these are coming from China, God knows where, and you are trusting them.
So, if you're going to trust somebody, you need to trust a physician with a compounding pharmacy during this course.
Now, phase 3 trials are still ongoing for this, though.
LIDL is conducting the full clinical trial program.
So, it's not clear, the full regulatory process that FDA approved drugs go through.
Right now, we are in May 2026.
May 2026.
And, we are looking maybe for another year for FDA to approve things.
You know, our FDA is slow.
Now, that process exists for a reason, right?
Because, you know, FDA wants to make sure that, you know, it's safe for those manufacturers and vendors and what kind of data is there.
But, it comes with a cost.
These companies are spending hundreds of millions of dollars.
So, once it becomes a drug, it's going to be over $1,000.
Now, what is happening right now is that some compounding pharmacies are producing with a two-time for physicians.
We're prescribing it off-label with incremental practice.
And, that is completely legal.
All right?
Now, compounding pharmacies, as you know, they operate under state pharmacy board regulations.
And, there's actually certain federal oversight through FDA's framework as well.
But, they're not manufacturing FDA approved drugs.
Because, FDA approved drugs does not exist here.
So, this distinction matters.
You need to understand.
Now, a compounding pharmacy in the United States that is operating legitimately, licensed by the state board, following U.S. standards,
and working with licensed prescribers, is a very different situation from the gray market, from online peptide sellers that we talked about before.
It is not the same thing.
And, we still have it.
But, it is still not the same as FDA approved drugs from a major pharmaceutical manufacturer.
So, just so you understand, there are some nuances there.
Even for medications that come from compounding pharmacies, what it means practically.
You need a physician in mind.
Not a telehealth questionnaire.
Not some telehealth company, you know, telling you, you know, two-minute questionnaire and then sending you a medication.
Not an online form.
A physician who knows your medical history, your current medications, your diabetes, your medicines, your status, your plan.
And, who's monitoring your lab?
Who's monitoring or adjusting your medications?
Right?
So, these are important questions.
Because, getting into trouble is very easy when you play with fire.
The compounding pharmacy your doctor works with should be 503A or 503B logistic pharmacies in the United States.
It should have documented quality tests.
So, your doctor basically should have a relationship with that pharmacy and be able to account for its sourcing standards.
So, how does it compare?
Let's be direct about the comparison, right?
Solid weight loss.
Excellent cardiovascular data.
Well-understood safety profile.
After years on the map.
But, it is less tolerable.
Average weight loss is around 15%.
A good first-line option.
There's Zepatide, which is Mondrato or Zepound.
GLP-1, which is IQ.
Better weight loss than somatotide.
Better A1c reduction.
Growing cardiovascular data.
And, average weight loss.
Around 20-22% top.
Currently, the most powerful FDA-approved option in this class is Mondrato and Zepound.
However, at the third time, GLP-1 plus GIPs plus Glutathione.
That is the highest weight loss data seen in any drug in this class in history.
24-26% average in this case.
Some people are probably talking about 30%.
Dramatically higher amelioid expenditure due to glutathione activation.
And, it seems to have superior visceral fat reduction.
Which is very important for Zepatide.
So, full safety profile still being established in phase 3.
But, glutathione appears to be significantly more powerful than anything currently approved.
The trade-off is that the long-term safety data is still being weathered.
That is not a reason to dismiss it.
There is a reason to do it correctly.
With a physician.
Through a proper treatment.
And, monitoring.
Now, side effects.
You need to know what to expect, right?
Like all GLP-1 based therapies, the most common side effects are going to be gastrointestinal, right?
So, nausea, vomiting, slow digestion can happen.
Not that it will happen, but it may happen.
You have to start with the slower dose of glucose.
Because, these are typically dose-dependent.
So, your doctor could be spotting you low and going slow.
Because, Zepatide so effectively lowers blood sugar.
Diabetics on insulin or sulfonylureas need to have their dose dropped every now and then.
If your doctor puts you on Zepatide and does not immediately talk about adjusting with other diabetes medications.
That is a conversation you need to initiate.
There are also theoretical concerns being studied around thyroid C-cell tumors.
This is a cross-wide concern with GLP-1 receptor agonists.
People with personal or family history of medullary thyroid carcinoma.
Not a papillary thyroid carcinoma.
Not a follicular thyroid carcinoma.
Not a thyroid nodule.
Not a goiter.
People get mixed up with these.
It is only for medullary thyroid carcinoma, which is very rare.
Very, very rare.
Or MEN-2 syndrome.
So, these people should not be on this class of drugs.
At the bottom line, Zepatide is the most promising metabolic peptide in clinical development right now.
The weight loss data is on prospect.
The mechanism for diabetics is multi-targeted and logical.
Patients in physician-supervised settings are achieving outcomes that older drug classes could not touch.
When I say physician, I'm not talking about wellness clinics where you go see a nurse practitioner.
Or, if you're a nurse, not a nurse practitioner.
That's not what I'm talking about.
I'm talking about a real specialist, preferably in endocrinology, who understands these drugs very well.
And it's not FDA approved.
Remember that.
That matters.
But, compounded access through a licensed physician in a legitimate CF compounding pharmacy is a real pathway.
Right now, for patients who have struggled with other therapies, cannot tolerate them, the FDA approved therapies, etc.
So, you need to understand that context.
This is not your first option.
Okay?
And this is not a supplement by any means.
And this is not a research peptide from an online vendor either.
So, this is a clinical decision between you and your doctor.
So, have that conversation in your lab, in your history,
and ask specifically whether you are a candidate for a drug medication at that time.
That's diabetes, thyroid, and hormones control for treasure troves.
That's what we do right here in Port St. Lucie.
Because if Phase III data holds, and right now, every sign says it will,
the approved type is going to change the entire landscape of obesity and diabetes.
The question is, whether you want to wait for the label, and pay for executive rights,
or get ahead of it right away by talking to your doctor to get it right.